Moderna 's (NASDAQ: MRNA) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

We recently compiled a list of the Jim Cramer’s Top 12 Must-Watch Stocks. In this article, we are going to take a look at ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Moderna’s cost-reduction plans, pipeline cuts and reined-in financial guidance, unveiled Thursday, triggered a wave of ...

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...

The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...

Present Market Standing of Moderna Trading volume stands at 5,013,059, with MRNA's price down by -2.52%, positioned at $68.1. RSI indicators show the stock to be may be approaching oversold. Earnings ...

Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock ...

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

Shares of Moderna rose after the company said that the government of Canada authorized its updated Covid-19 vaccine, joining the U.S. in the approval. The stock was up 4.5% at $72.28 in Tuesday ...